A new means of prostate cancer screening could emerge as an alternative to the PSA test, which has long been the first-line option. Using machine learning, a form of artificial intelligence ...

The Decipher Prostate Metastatic test is now available for metastatic prostate cancer, covered by Medicare for all risk levels. It helps clinicians determine which patients may benefit from treatment, ...

A newly published study indicates that prostate cancer can be diagnosed at an early stage through a simple urine sample. With the aid of AI and extensive analyses of gene activity in tumors ...

A new spit test for prostate cancer which can be done at home may be better than current testing methods, a study suggests. Experts have developed a simple saliva test which analyses genetic ...

More information: Martin Smelik, et al. Combining Spatial Transcriptomics, Pseudotime, and Machine Learning Enables Discovery of Biomarkers for Prostate Cancer, Cancer Research (2025). DOI: 10. ...

PROSTATE cancer could be detected early by a simple urine test, according to new research. The breakthrough could potentially save thousands of lives as it is the most common cancer among men in ...

The Decipher Prostate test’s clinical validity and clinical utility for use in patients with metastatic prostate cancer have been demonstrated in multiple, prospective, Phase 3 clinical studies.

Scientists writing in the New England Journal of Medicine said a genetic test using saliva is more accurate than a PSA blood test to assess prostate cancer risk. A new at-home spit test is better ...

It could prove “a game changer” for prostate cancer research as a whole, he added. At present, a blood test is used to look for elevated levels of prostate-specific antigen (PSA), a protein ...

A new at-home spit test for prostate cancer may be better than current testing methods, a new study has suggested. Experts have developed a new saliva test which analyses genetic variants in a man ...

SOUTH SAN FRANCISCO, Calif. - Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company with a market capitalization of $2.51 billion and impressive revenue growth of 23.46% in the last twelve ...